I
Indivior
A global pharmaceutical company working to help change patients’ lives by pioneering life-transforming treatment for addiction and other serious mental illnesses
About Indivior
Indivior is a global pharmaceutical company dedicated to developing medicines that treat substance use disorders and serious mental illnesses. The company operates in the healthcare sector, focusing on patients who suffer from addiction and mental health issues. Indivior's business model revolves around research and development of innovative treatments, which are then brought to market to improve patient outcomes. The company generates revenue through the sale of its pharmaceutical products, which are prescribed by healthcare professionals and used by patients worldwide. Indivior's commitment to patient safety and high-quality treatments is evident in its rigorous monitoring and reporting systems for product concerns and adverse events. By addressing critical healthcare needs, Indivior aims to create sustainable value and make a significant impact on global health.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Bon Air, United States
- Listing
- IPO 2014
- Employees
- 903
- Open positions
- 16
- Dealroom signal
- 63.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Verified Unicorns and $1B Exits, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 4 companies, latest Aug 2026
- Capital deployed
- —
- Preferred round
- POST IPO EQUITY
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGER✓Other financing | Aug 2026 | $0 | — | Supernus Pharmaceuticals | ↗ |
| POST IPO CONVERTIBLE✓Other financing | Mar 2026 | $450M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Indivior is 26K monthly website visits, up 0% over the last three months. Indivior's team declined 25.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Supernus PharmaceuticalsRockville, United StatesSpecialty pharmaceutical firm commercializing central nervous system treatments
$2.2Bvaluation
Addex TherapeuticsGeneva, SwitzerlandDiscovers and develops small molecule oral drugs to treat a range of medical conditions
$2.5Mvaluation
OpiantSanta Monica, United StatesAn IT company that specializes in web development, app development, software, web design, and project management services
$145Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Oaktree Capital Management
Other known investors2 additional known investors
- Supernus Pharmaceuticals
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Indivior on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Indivior’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.